Cooper Financial Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$352K Buy
14,633
+1,883
+15% +$49.3K 0.03% 313
2026
Q1
$358K Buy
12,750
+1,757
+16% +$46.8K 0.04% 297
2025
Q4
$274K Sell
10,993
-343
-3% -$8.65K 0.03% 317
2025
Q3
$289K Sell
11,336
-2,069
-15% -$51.1K 0.03% 304
2025
Q2
$325K Sell
13,405
-4,909
-27% -$114K 0.04% 285
2025
Q1
$464K Buy
18,314
+1,716
+10% +$44.9K 0.06% 246
2024
Q4
$440K Sell
16,598
-2,094
-11% -$56.8K 0.05% 260
2024
Q3
$541K Sell
18,692
-225
-1% -$6.56K 0.07% 234
2024
Q2
$529K Buy
18,917
+9,831
+108% +$271K 0.08% 213
2024
Q1
$252K Sell
9,086
-186
-2% -$5.16K 0.04% 311
2023
Q4
$267K Buy
9,272
+58
+0.6% +$1.75K 0.05% 288
2023
Q3
$306K Sell
9,214
-9,017
-49% -$319K 0.07% 257
2023
Q2
$669K Sell
18,231
-6,702
-27% -$261K 0.17% 150
2023
Q1
$1.02M Buy
24,933
+5,957
+31% +$257K 0.27% 93
2022
Q4
$972K Buy
18,976
+633
+3% +$30.3K 0.3% 84
2022
Q3
$803K Buy
18,343
+647
+4% +$31.4K 0.29% 88
2022
Q2
$928K Buy
17,696
+1,938
+12% +$98.8K 0.34% 79
2022
Q1
$816K Buy
15,758
+5,959
+61% +$309K 0.31% 70
2021
Q4
$579K Sell
9,799
-3,420
-26% -$169K 0.22% 106
2021
Q3
$569K Buy
13,219
+160
+1% +$7.09K 0.12% 118
2021
Q2
$511K Sell
13,059
-55
-0.4% -$2.14K 0.1% 120
2021
Q1
$475K Sell
13,114
-4,571
-26% -$162K 0.11% 128
2020
Q4
$651K Buy
17,685
+5,212
+42% +$191K 0.13% 128
2020
Q3
$434K Buy
12,473
+486
+4% +$17K 0.13% 117
2020
Q2
$372K Buy
11,987
+2,769
+30% +$94.1K 0.12% 117
2020
Q1
$285K Buy
9,218
+3,176
+53% +$108K 0.12% 110
2019
Q4
$225K Sell
6,042
-818
-12% -$29.1K 0.09% 141
2019
Q3
$234K Sell
6,860
-5,853
-46% -$213K 0.11% 123
2019
Q2
$523K Buy
12,713
+1,145
+10% +$45.5K 0.25% 62
2019
Q1
$466K Sell
11,568
-1,058
-8% -$42.4K 0.26% 58
2018
Q4
$523K Buy
+12,626
New +$524K 0.35% 44

Other funds holding PFE

Cooper Financial Group's PFE Position: Q2 2026 in Review

Cooper Financial Group increased its Pfizer (PFE) stake by 15% in Q2 2026, buying an estimated $49.3K and bringing the position to 14,633 shares worth $352K. The position accounts for 0.03% of the portfolio, ranked #313.

Cooper Financial Group first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.02M in Q1 2023. 457 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Cooper Financial Group held 14,633 shares of Pfizer worth $352K as of Q2 2026.
  • Cooper Financial Group bought 1,883 Pfizer shares in Q2 2026, an estimated $49.3K.
  • Pfizer made up 0.03% of Cooper Financial Group's portfolio in Q2 2026, its #313 holding.
  • Cooper Financial Group first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
  • Cooper Financial Group's Pfizer position peaked at $1.02M in Q1 2023.
  • 457 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Cooper Financial Group's 13F filing for Q2 2026, filed 8 Jul 2026.